Updated 02:01 GMT, 17 Nov 2026 SPX 7,416.59 -1.92% NDX 27,197.15 -2.67% VIX 22.91 +18.70% GOLD 3,868.50 -0.46% CL 85.14 -3.86% BTC 65,305.22 0.00%
NAS100 27,197 −2.67% S&P 7,417 −1.92% GOLD $3,869 −0.46% BTC $65,305 VIX 22.91 +18.70% latest tape · as of 02:01 UTC
The Screen · Consumer Cyclical · Luxury Goods

AsiaStrategy

SORA · NASDAQ · USD · Market cap $43M · 7 employees

AsiaStrategy, together with its subsidiaries, engages in trading, distribution, and retail of luxury watches in Hong Kong.

FAIL · Does not pass the screen
2.20 USD

Price as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago

Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price2.20 USD at the 13 Nov 2026 close
  • Our regime readAccumulation, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed13 Nov 2026 (4 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-13).

Current read
Accumulation ?
Screened · screened 2026-11-13
  • Trend Accumulation
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price2.20 USD
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Accumulation2.22-0.9% to today Markdown gives way to Accumulation after a 28% rise in 3 weeks
2026-09-13Read Markdown1.73+27.2% to today Markup gives way to Markdown first Markdown read since July
2026-08-13Read Markup1.73+27.2% to today ✓Markdown gives way to Markup after a 25% slide in 6 weeks
2026-07-02Read Markdown2.31-4.8% to today ✓First review on file: Markdown

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

AsiaStrategy holds its Accumulation at $2.20. The statistical read favours the sellers, held for 35 days.

As held on the ledger · 2026-11-13
PhaseAccumulation
Quantitative stateThe statistical read favours the sellers, held for 35 days
Price at the screen$2.20
Valuation4.44 trailing · N/A forward price to earnings
Values screenFAIL · score 70.0
The Workings

Five Screens, Shown in Full

Does not pass. Debt ratio

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 35.65% Below 33% Interest-bearing debt is 35.6% of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash 8.76% Below 33% Cash held in interest-bearing accounts and securities is 8.8% of assets, under the one-third limit. Pass
Receivables 3.79% Below 49% Money owed to the company is 3.8% of assets, under the 49% limit. Pass
Revenue purity 1.10% Below 5% Only 1.1% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

AsiaStrategy's business is in a permissible area, but its interest-bearing debt is about 36% of the company, just over the ~33% line, so it does not pass on the financial screens.

Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when SORA's ethical verdict changes

Today SORA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

The Business, in Plain Words
The fundamentals · plain-English read
Trailing P/E4.4xvery cheap relative to earnings
EPS, trailing0.50
Revenue growth-31.9%revenue is shrinking
Profit margin111.9%highly profitable on every dollar of sales
Return on equity106.1%an exceptional return on shareholder capital
FCF yield-16.89%
Debt to equity0.65moderate, manageable leverage
Current ratio6.51comfortably covers its short-term bills
Short interest, float0.00%
52-week range1.25 - 7.23
MoatNONE
Market cap$43M
Employees7

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Hong Kong and to currency swings.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

SORA trades on NASDAQ (the company is based in Hong Kong). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-14 Accumulation $2.20 -10.2% Entry 9

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 10.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 69%. Our forward projection puts the odds of a 10% gain over the next month near 29%.

2026-11-03 Accumulation $2.45 -0.8% Entry 8

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 69%. Our forward projection puts the odds of a 10% gain over the next month near 29%.

2026-10-22 Accumulation $2.47 +11.3% Entry 7

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 11.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 69%. Our forward projection puts the odds of a 10% gain over the next month near 29%.

2026-10-02 Accumulation · changed $2.22 +28.3% Entry 6

The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 28.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 69%. Our forward projection puts the odds of a 10% gain over the next month near 29%.

2026-09-13 Markdown · changed $1.73 +0.0% Entry 5

The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 69%. Our forward projection puts the odds of a 10% gain over the next month near 29%.

2026-08-13 Markup · changed $1.73 -25.1% Entry 4

The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 25.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 69%. Our forward projection puts the odds of a 10% gain over the next month near 29%.

2026-07-18 Markdown $2.31 +0.0% Entry 3

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 69%. Our forward projection puts the odds of a 10% gain over the next month near 29%.

2026-07-03 Markdown $2.31 +0.0% Entry 2

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.

2026-07-02 Markdown $2.31 Entry 1

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Related Securities · Others in SORA's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $2.53 -15.0% · $850 -15.0%
2 months $1.89 +13.8% · $1,138 +13.8%
3 months $1.97 +9.1% · $1,091 +9.1%
6 months $3.87 -44.4% · $556 -44.4%
1 year $6.86 -68.7% · $313 -68.7%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever SORA does next, these words stay.

AsiaStrategy · SORA · Accumulation · $2.20
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.